RINVOQ 15 mg


prolonged-release tablets
scheduling status
S4
registration number
54/3.1/0187
What RINVOQ 15 mg contains
Upadacitinib hemihydrate.
other ingredients
Microcrystalline cellulose, Hypromellose, Mannitol, Tartaric acid, Silica (colloidal anhydrous), Magnesium stearate.
Therapeutic classification
L04AA44.
© 2026 SAHPRA. ALL RIGHTS RESERVED